Companies:64525
FatCapitalist:Apple Inc. [AAPL]United States

Palatin Technologies, Inc. [PTNUnited States

NYSE American exchange. Sector: Healthcare. Industry: Biotechnology. Location United States, Cranbury.
At close Fri Sep 30 2022
5.92 USD 👎0.2 (-3.38%)

At close Fri Sep 30 2022

Marketcap
1,369,562,368 USD

Marketcap

PE:.
BETA (5y):1.099
EPS:-0.117
Profits

for 5 years

1,456%

for 3 years

825%

for 2 years

882%

for 1 year

625%

for this year

1,318%
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

We discover and develop novel therapeutics for patients living with inflammatory and autoimmune conditions.

Palatin Technologies, Inc.
© 2022 avazzy.com. All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.